Apogee Therapeutics (APGE) Equity Ratio (2022 - 2026)

Apogee Therapeutics (APGE) has 5 years of Equity Ratio data on file, last reported at 0.97 in Q1 2026.

• Quarterly Equity Ratio rose 2.96% year-over-year to 0.97 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.97 (up 2.96% YoY) and the FY2025 annual result came in at 0.96, up 1.45% from the prior year.
• Equity Ratio grew to 0.97 in Q1 2026 per APGE's latest filing, from 0.96 in the prior quarter.
• Across five years, Equity Ratio topped out at 0.97 in Q1 2024 and bottomed at 0.49 in Q2 2023.
• The 5-year median for Equity Ratio is 0.95 (2023), against an average of 0.75.
• The widest annual swing landed in 2023, when Equity Ratio jumped 506.63%; it then slipped 3.1% in 2025.
• Tracing APGE's Equity Ratio over 5 years: stood at 0.23 in 2022, then jumped by 506.63% to 0.95 in 2023, then increased by 0.45% to 0.95 in 2024, then rose by 1.45% to 0.96 in 2025, then increased by 0.64% to 0.97 in 2026.
• Per Business Quant, the three latest APGE Equity Ratio figures stand at 0.97 (Q1 2026), 0.96 (Q4 2025), and 0.94 (Q3 2025).

Peer Comparison